Plain-English translation of NCT04656041 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether liposomal irinotecan, combined with other standard chemotherapy drugs and radiation therapy, works better for treating advanced esophageal and stomach cancer. The researchers want to see if adding this medication to the usual treatment plan helps patients live longer and have better outcomes. Most of the drugs in this combination are already approved for this type of cancer, but liposomal irinotecan is new for this specific disease.
Right now, patients with advanced esophageal and stomach cancer have limited treatment options and outcomes are often poor. This trial exists to see whether this medication, when combined with standard chemotherapy and radiation, can improve survival and give patients a better chance of beating their cancer.
You likely qualify if…
You likely don't qualify if…
You will receive eight cycles of chemotherapy over 16 weeks as an outpatient (meaning you go home after each treatment). Then you will receive five weeks of concurrent chemotherapy and radiation therapy. After completing chemotherapy and radiation, you will have surgery to remove the cancer. Throughout the trial, you'll have regular visits with the research team for blood tests, scans, and checkups to monitor how you're responding to treatment.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
United States